NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
52 hedge funds and large institutions have $43.1M invested in NeuBase Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 11 closing their positions.
89% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $1.03M
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
9% less funds holding
Funds holding: 57 → 52 (-5)
23% less capital invested
Capital invested by funds: $55.8M → $43.1M (-$12.8M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.34M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$989K |
| 3 |
VAM
Visium Asset Management
New York
|
+$691K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$413K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.35M |
| 2 |
Goldman Sachs
New York
|
-$589K |
| 3 |
Jane Street
New York
|
-$480K |
| 4 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$245K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$169K |
NBSE Hedge Fund Activity: Q3 2014 in Review
52 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2014, worth a combined $43.1M — down 23% from $55.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NBSE and 6 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 18 added.
The largest buyer was Northern Trust, adding an estimated $1.34M. The largest seller was Millennium Management, cutting an estimated $1.35M.
- 52 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2014, down from 57 in Q2 2014.
- Funds reported $43.1M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2014, down 23% quarter-over-quarter.
- 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2014 and 11 closed out, a net change of -5 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2014 was Northern Trust, an estimated $1.34M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2014 was Millennium Management, an estimated $1.35M sold.
Based on aggregated 13F filings for Q3 2014.